Meghmani Organi.

Why is Meghmani Organics Ltd falling/rising?

As of 30-Aug, Meghmani Organics Ltd's stock price is rising to 60.98, reflecting a 1.04% increase due to outperforming its sector and a trend reversal after previous declines. Despite reduced investor participation, the stock remains liquid and above key moving averages, indicating a bullish trend.

As of 30-Aug, Meghmani Organics Ltd's stock price is rising, currently at 60.98, with a change of 0.63 (1.04%) upwards. This upward movement can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 0.59%, indicating stronger performance relative to its peers. Additionally, there has been a trend reversal, as the stock has gained after three consecutive days of decline, suggesting a potential shift in investor sentiment.<BR><BR>Moreover, the stock's current price is higher than its 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bullish trend. However, it is worth noting that the stock is lower than its 5-day moving average, which may suggest some short-term volatility. <BR><BR>Despite a significant drop in investor participation, with delivery volume falling by 38.11% against the 5-day average, the stock remains liquid enough for trading, with a liquidity level based on 2% of the 5-day average traded value. Overall, these factors contribute to the current rise in Meghmani Organics Ltd's stock price.

Which are the latest news on Meghmani Organi.?

Who are in the management team of Meghmani Organi.?

The management team of Meghmani Organics includes Executive Chairman Jayanti M Patel, Managing Directors Ashish N Soparkar and Natwarlal M Patel, Executive Directors Ramesh M Patel and Anand I Patel, along with several Non-Executive and Independent Directors, including Urvashi Dhirubhai Shah and Varesh Sinha. This team is responsible for the company's governance and strategic direction.

The management team of Meghmani Organics includes the following key individuals:<BR><BR>1. **Jayanti M Patel** - Executive Chairman<BR>2. **Ashish N Soparkar** - Managing Director<BR>3. **Natwarlal M Patel** - Managing Director<BR>4. **Ramesh M Patel** - Executive Director<BR>5. **Anand I Patel** - Executive Director<BR>6. **Urvashi Dhirubhai Shah** - Non-Executive & Independent Director<BR>7. **Manubhai Khodidas Patel** - Non-Executive & Independent Director<BR>8. **Ganapati D Yadav** - Non-Executive & Independent Director<BR>9. **Jayesh Patel** - Company Secretary & Compliance Officer<BR>10. **Varesh Sinha** - Independent Director<BR>11. **Nikunt Raval** - Additional Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Meghmani Organi. do?

Meghmani Organics Ltd manufactures and sells pigment and agrochemical products, categorized as a micro-cap company with a market cap of INR 1,462 Cr. As of June 2026, it reported net sales of 543 Cr and a net profit of 48 Cr.

Overview: <BR>Meghmani Organics Ltd is engaged in the manufacturing and selling of pigment and agrochemical products within the pesticides and agrochemicals industry, categorized as a micro-cap company.<BR><BR>History: <BR>Meghmani Organics Ltd was originally incorporated as 'Meghmani Organochem Limited' on 15 October 2019. The company changed its name to "Meghmani Organics Limited" on 3rd August 2021. The most recent quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 543 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 48 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,462 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.45 <BR>Return on Equity: 1.86% <BR>Price to Book: 0.95<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Meghmani Organi.?

Peers of Meghmani Organics include Bhagiradha Chemicals, Bharat Rasayan, Insecticides India, India Pesticides, Astec Lifesciences, Punjab Chemicals, Dharmaj Crop, and Heranba Industries. Meghmani has below-average management risk and a 1-year return of -30.58%, better than Bharat Rasayan's -51.89% but worse than Bhagiradha Chemicals' -1.91%.

Peers: The peers of Meghmani Organi. are Bhagiradha Chem., Bharat Rasayan, Insecticid.India, India Pesticides, Astec Lifescienc, Punjab Chemicals, Dharmaj Crop, and Heranba Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bharat Rasayan, Insecticid.India, and India Pesticides, while Average management risk is found at Bhagiradha Chem., Punjab Chemicals, and Dharmaj Crop, and the rest. Below Average management risk is noted for Meghmani Organi., Astec Lifescienc, and Heranba Inds. Growth ratings are Below Average for Bhagiradha Chem., Bharat Rasayan, Insecticid.India, India Pesticides, Meghmani Organi., Astec Lifescienc, Punjab Chemicals, and Heranba Inds, while Good growth is seen at Dharmaj Crop and the rest. Capital Structure is Excellent for Bharat Rasayan, Insecticid.India, and India Pesticides, Good for Bhagiradha Chem. and Punjab Chemicals, Average for Meghmani Organi. and Heranba Inds, and Below Average for Astec Lifescienc.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bhagiradha Chem. at -1.91%, while the lowest is Bharat Rasayan at -51.89%. Meghmani Organi.'s 1-year return is -30.58%, which is better than Bharat Rasayan but worse than Bhagiradha Chem. Additionally, Astec Lifescienc, Heranba Inds, and Bharat Rasayan have negative six-month returns.

How big is Meghmani Organi.?

As of 14th August, Meghmani Organics Ltd has a market capitalization of 1,613.62 Cr, with recent net sales of 2,103.17 Cr and a net profit of 64.24 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Meghmani Organics Ltd has a market capitalization of 1,613.62 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,103.17 Cr, while the sum of Net Profit for the same period is 64.24 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,515.26 Cr, and Total Assets amount to 3,085.41 Cr.

Are Meghmani Organics Ltd latest results good or bad?

Meghmani Organics Ltd's latest results show a strong profit growth of 280.05% year-on-year, reaching ₹48.19 crore, but revenue declined by 11.54%, marking the third consecutive quarter of contraction. While profitability recovery is positive, ongoing revenue challenges and industry pressures create a cautious outlook.

Meghmani Organics Ltd's latest results present a mixed picture. On one hand, the company achieved a significant net profit of ₹48.19 crore for Q1 FY27, reflecting a remarkable year-on-year growth of 280.05%. This indicates a strong recovery in profitability, driven by improved operational efficiency and cost management, as evidenced by an operating margin of 18.04%, the highest in seven quarters.<BR><BR>However, the revenue for the same quarter was ₹542.83 crore, which represents an 11.54% decline compared to the previous year. This marks the third consecutive quarter of year-on-year revenue contraction, highlighting ongoing challenges in the market, particularly in the agrochemicals sector. Despite a positive sequential growth of 14.44% from the previous quarter, the persistent revenue decline raises concerns about the company's ability to sustain growth.<BR><BR>While the profitability recovery is encouraging, the overall outlook remains cautious due to the structural challenges facing the industry, including pricing pressures and competition. The elevated price-to-earnings ratio of 50 times also suggests that the market may be skeptical about the sustainability of this recovery.<BR><BR>In summary, while the profit growth is a positive sign, the ongoing revenue challenges and broader industry headwinds present significant risks, making the overall assessment of the latest results somewhat negative.

Should I buy, sell or hold Meghmani Organics Ltd?

When is the next results date for Meghmani Organics Ltd?

The next results date for Meghmani Organics Ltd is 29 July 2026.

The next results date for Meghmani Organics Ltd is scheduled for 29 July 2026.

Is Meghmani Organi. technically bullish or bearish?

As of November 14, 2025, Meghmani Organics has a bearish technical stance, indicated by bearish MACD, Bollinger Bands, moving averages, and KST across multiple timeframes, along with significant underperformance compared to the Sensex.

As of 14 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Meghmani Organics is bearish, with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on both weekly and monthly timeframes, while the Dow Theory indicates a mildly bearish outlook on the weekly and monthly. The stock has underperformed significantly compared to the Sensex across multiple timeframes, further supporting the bearish sentiment.

How has been the historical performance of Meghmani Organi.?

Meghmani Organi's historical performance has been volatile, with net sales peaking at 2,552.62 Cr in March 2023 before declining to 2,079.75 Cr by March 2025, alongside a drop in operating profit and ongoing challenges reflected in negative profit after tax of -10.60 Cr in March 2025. Total liabilities increased to 3,085.41 Cr, indicating financial strain despite some recovery in profit before tax.

Answer:<BR>The historical performance of Meghmani Organi shows significant fluctuations in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Meghmani Organi's net sales peaked at 2,552.62 Cr in March 2023 but declined to 2,079.75 Cr by March 2025. The total operating income followed a similar trend, decreasing from 2,552.62 Cr in March 2023 to 2,079.75 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline, reaching 186.62 Cr in March 2025 after a high of 474.75 Cr in March 2022. The profit before tax turned positive again in March 2025 at 9.47 Cr, recovering from a loss of 121.18 Cr in March 2024. However, the profit after tax remained negative at -10.60 Cr in March 2025, indicating ongoing challenges. The company's total liabilities increased from 2,797.61 Cr in March 2022 to 3,085.41 Cr in March 2025, while total assets also rose to 3,085.41 Cr in March 2025. Cash flow from operating activities decreased to 66.00 Cr in March 2025, down from 333.00 Cr in March 2021, reflecting a decline in operational efficiency. Overall, Meghmani Organi's financial performance has been volatile, with notable highs and lows across various metrics.

Is Meghmani Organi. overvalued or undervalued?

As of November 10, 2025, Meghmani Organics is considered undervalued with an attractive valuation grade, a PE ratio of 46.23, and strong growth potential, especially when compared to peers like Sudarshan Chemicals and Kiri Industries, despite its recent underperformance against the Sensex.

As of 10 November 2025, the valuation grade for Meghmani Organics has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, particularly given its PE ratio of 46.23, an EV to EBITDA of 34.63, and a PEG ratio of 0.31, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Meghmani stands out with a more favorable valuation than Sudarshan Chemicals, which is deemed expensive with a PE of 96.51, and Kiri Industries, which is classified as risky with a PE of 26.11. Additionally, while the stock has underperformed against the Sensex over various periods, including a 1-year decline of 29.12% compared to the Sensex's 5.09% gain, the attractive valuation suggests potential for recovery and growth in the future.

Who are the top shareholders of the Meghmani Organi.?

The top shareholders of Meghmani Organi include promoter Ashishbhai Natawarlal Soparkar with 10.59%, 45 Foreign Institutional Investors holding 1.81%, and public shareholder Gadia Naveen Vishwanath with 1.35%. Individual investors collectively own 37.9% of the shares.

The top shareholders of Meghmani Organi include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ashishbhai Natawarlal Soparkar, who owns 10.59% of the company. Additionally, there are 45 Foreign Institutional Investors (FIIs) holding a combined 1.81% of the shares. The highest public shareholder is Gadia Naveen Vishwanath, with a holding of 1.35%. Individual investors collectively hold 37.9% of the shares.

Has Meghmani Organi. declared dividend?

Yes, Meghmani Organics Ltd has declared a 140% dividend, amounting to ₹1.4 per share, with an ex-date of June 20, 2023. However, the total returns over various periods have shown mixed performance, with a lack of dividend yield indicating minimal impact on overall returns.

Meghmani Organics Ltd has declared a 140% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 1.4<BR>- Ex-date: 20 Jun 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.3%, the dividend return was 0%, resulting in a total return of -4.3%.<BR><BR>Over the past year, the price return was 14.07%, the dividend return was 0%, leading to a total return of 14.07%.<BR><BR>For the 2-year period, the price return was 4.44%, the dividend return was 1.59%, resulting in a total return of 6.03%.<BR><BR>In the 3-year period, the price return was -30.83%, the dividend return was 1.26%, leading to a total return of -29.57%.<BR><BR>Over the last 4 years, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Meghmani Organics Ltd has declared a significant dividend, the total returns over various periods show mixed performance, particularly with negative returns in the short and long term. The lack of dividend yield indicates that the dividend has not significantly impacted the overall returns.